Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

DRIVE Trial (Dialysis Patients' Response to Intravenous [IV] Iron With Elevated Ferritin) (DRIVE)

This study has been completed.
Information provided by (Responsible Party):
Watson Pharmaceuticals Identifier:
First received: September 13, 2005
Last updated: December 8, 2015
Last verified: December 2015
This study explores the safety and efficacy of intravenous iron therapy in anemic hemodialysis patients treated with epoetin alfa, who have higher serum ferritin levels, but low to normal transferrin saturation.

Condition Intervention Phase
Anemia, Iron-Deficiency
Kidney Failure, Chronic
Drug: Sodium ferric gluconate,
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Dialysis Patients' Response to IV Iron With Elevated Ferritin

Resource links provided by NLM:

Further study details as provided by Watson Pharmaceuticals:

Primary Outcome Measures:
  • Change in hemoglobin and anemia medications [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change in various iron indices [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]

Enrollment: 134
Study Start Date: September 2004
Primary Completion Date: May 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ferric gluconate Drug: Sodium ferric gluconate,
Sodium ferric gluconate, 125 mg IV given at 8 consecutive hemodialysis sessions
No Intervention: standard of care


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Chronic hemodialysis
  • Elevated serum ferritin with low to normal transferrin saturation (TSAT)
  • Moderate to severe anemia
  • Receiving epoetin alfa treatment

Exclusion Criteria:

  • Known sensitivity to Ferrlecit®
  • Medical conditions that would confound the efficacy evaluation
  • Recent blood transfusion
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00224081

  Show 29 Study Locations
Sponsors and Collaborators
Watson Pharmaceuticals
Study Director: Adel R. Rizkala, Pharm.D., MS Watson Laboratories, Inc.
  More Information

Responsible Party: Watson Pharmaceuticals Identifier: NCT00224081     History of Changes
Other Study ID Numbers: FER0401 
Study First Received: September 13, 2005
Last Updated: December 8, 2015
Health Authority: United States: Institutional Review Board

Keywords provided by Watson Pharmaceuticals:
iron deficiency anemia
sodium ferric gluconate
epoetin alfa

Additional relevant MeSH terms:
Anemia, Iron-Deficiency
Renal Insufficiency
Kidney Failure, Chronic
Anemia, Hypochromic
Hematologic Diseases
Iron Metabolism Disorders
Metabolic Diseases
Kidney Diseases
Urologic Diseases
Renal Insufficiency, Chronic
Ferric gluconate
Ferric Compounds
Hematinics processed this record on October 21, 2016